Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study
Uloženo v:
| Název: | Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study |
|---|---|
| Autoři: | Sissel J Godtfredsen, Kristian H Kragholm, Peter Leutscher, Steen Hylgaard Jørgensen, Martin Kirk Christensen, Jawad H Butt, Gunnar Gislason, Lars Køber, Emil L Fosbøl, Maurizio Sessa, Deepak L Bhatt, Christian Torp-Pedersen, Manan Pareek |
| Zdroj: | Godtfredsen, S J, Kragholm, K H, Leutscher, P, Jørgensen, S H, Christensen, M K, Butt, J H, Gislason, G, Køber, L, Fosbøl, E L, Sessa, M, Bhatt, D L, Torp-Pedersen, C & Pareek, M 2022, 'Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention : a nationwide registry-based study', European Heart Journal: Acute Cardiovascular Care, vol. 11, no. 9, zuac095, pp. 697-705. https://doi.org/10.1093/ehjacc/zuac095 |
| Informace o vydavateli: | Oxford University Press (OUP), 2022. |
| Rok vydání: | 2022 |
| Témata: | Platelet Aggregation Inhibitors/adverse effects, Ticagrelor, ST Elevation Myocardial Infarction/drug therapy, PREHOSPITAL TICAGRELOR, Hemorrhage, Clopidogrel/therapeutic use, VALIDATION, Prasugrel Hydrochloride/therapeutic use, 03 medical and health sciences, Percutaneous Coronary Intervention, 0302 clinical medicine, Hemorrhage/chemically induced, Humans, Registries, Percutaneous Coronary Intervention/adverse effects, OUTCOMES, Aspirin, DUAL ANTIPLATELET THERAPY, OPEN-LABEL, RANDOMIZED-TRIAL, Clopidogrel, 3. Good health, Treatment Outcome, Ticagrelor/therapeutic use, Purinergic P2Y Receptor Antagonists/adverse effects, Purinergic P2Y Receptor Antagonists, PLATELET INHIBITION, ST Elevation Myocardial Infarction, REVASCULARIZATION, Prasugrel, Prasugrel Hydrochloride, Platelet Aggregation Inhibitors, ST-segment myocardial infarction |
| Popis: | Aims To compare the effectiveness and safety of clopidogrel, ticagrelor, and prasugrel in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). Methods and results Nationwide, registry-based study of STEMI patients treated with primary PCI (2011–17) and subsequently with aspirin and a P2Y12 inhibitor. The effectiveness outcome was major adverse cardiovascular events (MACE) defined as a composite of recurrent myocardial infarction, repeat revascularization, stroke, or cardiovascular death at 12 months. The safety outcome was bleeding requiring hospitalization at 12 months. Multivariable logistic regression with average treatment effect modeling was used to calculate absolute and relative risks for outcomes standardized to the distributions of demographic characteristics of all included subjects. We included 10 832 patients; 1 697 were treated with clopidogrel, 7 508 with ticagrelor, and 1,627 with prasugrel. Median ages were 66, 63, and 59 years (P Conclusion Ticagrelor and prasugrel were associated with lower risks of MACE after STEMI than clopidogrel, and ticagrelor was associated with a marginal reduction compared with prasugrel. The risk of bleeding was lower with ticagrelor compared with clopidogrel, but did not significantly differ between ticagrelor and prasugrel. |
| Druh dokumentu: | Article |
| Jazyk: | English |
| ISSN: | 2048-8734 2048-8726 |
| DOI: | 10.1093/ehjacc/zuac095 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/35950769 https://vbn.aau.dk/da/publications/19f3f161-9804-4191-9547-e2c3e620f7f9 https://doi.org/10.1093/ehjacc/zuac095 |
| Rights: | OUP Standard Publication Reuse |
| Přístupové číslo: | edsair.doi.dedup.....79103f4edb5e6a6dd5bf56a7c48cd1a6 |
| Databáze: | OpenAIRE |
Nájsť tento článok vo Web of Science | Abstrakt: | Aims To compare the effectiveness and safety of clopidogrel, ticagrelor, and prasugrel in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). Methods and results Nationwide, registry-based study of STEMI patients treated with primary PCI (2011–17) and subsequently with aspirin and a P2Y12 inhibitor. The effectiveness outcome was major adverse cardiovascular events (MACE) defined as a composite of recurrent myocardial infarction, repeat revascularization, stroke, or cardiovascular death at 12 months. The safety outcome was bleeding requiring hospitalization at 12 months. Multivariable logistic regression with average treatment effect modeling was used to calculate absolute and relative risks for outcomes standardized to the distributions of demographic characteristics of all included subjects. We included 10 832 patients; 1 697 were treated with clopidogrel, 7 508 with ticagrelor, and 1,627 with prasugrel. Median ages were 66, 63, and 59 years (P Conclusion Ticagrelor and prasugrel were associated with lower risks of MACE after STEMI than clopidogrel, and ticagrelor was associated with a marginal reduction compared with prasugrel. The risk of bleeding was lower with ticagrelor compared with clopidogrel, but did not significantly differ between ticagrelor and prasugrel. |
|---|---|
| ISSN: | 20488734 20488726 |
| DOI: | 10.1093/ehjacc/zuac095 |